Opaleye Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Opaleye Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.6M	Sell	122,500 -500	-0.4%	-$45.2K	1.23%	23
2026 Q1	$35.3M	Sell	123,000 -207,000	-63%	-$20.1M	4.65%	5
2025 Q4	$35.3M	Sell	330,000 -131,700	-29%	-$14M	4.66%	4
2025 Q3	$46.6M	Sell	461,700 -13,300	-3%	-$1.23M	6.59%	4
2025 Q2	$30M	Sell	475,000 -15,000	-3%	-$918K	6.07%	7
2025 Q1	$26M	Sell	490,000 -10,000	-2%	-$555K	5.78%	5
2024 Q4	$28M	Hold	500,000	–	–	4.9%	7
2024 Q3	$26.2M	Sell	500,000 -15,000	-3%	-$719K	4.37%	6
2024 Q2	$21.1M	Hold	515,000	–	–	4.83%	4
2024 Q1	$22.3M	Sell	515,000 -95,000	-16%	-$4.16M	4.86%	5
2023 Q4	$28M	Sell	610,000 -43,000	-7%	-$1.36M	7.46%	4
2023 Q3	$15M	Sell	653,000 -82,000	-11%	-$1.84M	4.87%	5
2023 Q2	$12.1M	Hold	735,000	–	–	2.9%	8
2023 Q1	$13.1M	Hold	735,000	–	–	3.93%	4
2022 Q4	$21.4M	Sell	735,000 -75,000	-9%	-$1.93M	7.44%	3
2022 Q3	$19.8M	Buy	810,000 +448,000	+124%	+$8.33M	8.2%	3
2022 Q2	$1.5M	Buy	+362,000	New	+$1.98M	0.68%	33
2021 Q1	–	Sell	-115,000	Closed	-$3.42M	–	65
2020 Q4	$3.42M	Buy	+115,000	New	+$2.92M	0.45%	45
2020 Q1	–	Sell	-110,500	Closed	-$2.54M	–	51
2019 Q4	$2.54M	Buy	+110,500	New	+$2.45M	0.5%	42
2018 Q1	–	Sell	-38,300	Closed	-$1.11M	–	44
2017 Q4	$1.11M	Buy	+38,300	New	+$1.01M	0.36%	32

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Opaleye Management's RYTM Position: Q2 2026 in Review

Opaleye Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 0.41% in Q2 2026, selling an estimated $45.2K and leaving 122,500 shares worth $13.6M. The position accounts for 1.23% of the portfolio, ranked #23.

Opaleye Management first reported a position in RYTM in Q4 2017 and has held it in 20 quarters since. The position peaked at $46.6M in Q3 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Opaleye Management held 122,500 shares of Rhythm Pharmaceuticals worth $13.6M as of Q2 2026.
Opaleye Management sold 500 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $45.2K.
Rhythm Pharmaceuticals made up 1.23% of Opaleye Management's portfolio in Q2 2026, its #23 holding.
Opaleye Management first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 20 quarters since.
Opaleye Management's Rhythm Pharmaceuticals position peaked at $46.6M in Q3 2025.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.